Companies › Biocity Biopharmaceutics
3 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 3; Oncology, Genitourinary; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SC0062 | – | Phase 3 | IgA Nephropathy (IgAN) | Dec 2026 |
| BC3195 anti-CDH3 antibody-drug conjugate with MMAE payload | CDH3 | Phase 1 | Advanced Cancer; Locally Advanced or Metastatic Solid Tumors | Apr 2027 |
| BC2027 for Injection | – | Phase 1 | Advanced Solid Malignancies | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06819826 | SC0062 | Phase 3 | IgA Nephropathy (IgAN) | Genitourinary | Dec 2026 |
| NCT06548672 | BC3195 | Phase 1 | Advanced Cancer | Oncology | Apr 2027 |
| NCT07368478 | BC2027 for Injection | Phase 1 | Advanced Solid Malignancies | Oncology | Dec 2027 |
| NCT07469774 | BC3195 | Phase 1 | Locally Advanced or Metastatic Solid Tumors | Oncology | Dec 2027 |
–
Day One Biopharmaceuticals Nuvalent RayzeBio BioRay Pharmaceutical Stemline Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.